Navigation Links
New Research May Encourage Smokers to Jump-Start Their New Year's Resolution to Quit Smoking

PITTSBURGH, Dec. 8 /PRNewswire/ -- While New Year's is the most popular time to try quitting smoking, research shows the majority of smokers who try to quit at that time resume smoking in less than one week.(1) By starting a quit attempt early, smokers can avoid the pressures of a New Year's resolution and may be well on their way toward being smoke-free by January 1st. New research shows that smokers who use the 21 mg NicoDerm(R) CQ(R) nicotine patch every day for the first three weeks of a 10-week treatment significantly improve their chances of success.(2)

The study, published in the November issue of Clinical Therapeutics: The International Peer-Reviewed Journal of Drug Therapy, shows that people who use the 21 mg NicoDerm CQ nicotine patch every day for the first 21 days of quitting were three-times as likely of being smoke-free at the six week point in the course of treatment compared to those who do not wear their patch every day.(2) Further, when used as directed, the NicoDerm CQ patch can significantly increase a smoker's chance of quitting (versus placebo) and remaining smoke-free long-term (6 months or longer).(3)

"Quitting smoking can be one of the toughest New Year's resolutions to keep. The NicoDerm CQ nicotine patch is a hassle free approach to quitting smoking as smokers only need to apply it once-daily," said Saul Shiffman, Ph.D., lead researcher and professor in the departments of psychology and pharmaceutical science at the University of Pittsburgh. "While a smoker may slip and have a cigarette during the quitting process, by no means should they abandon quitting altogether. Smokers should keep wearing the NicoDerm CQ patch every day and it will keep working for you, even if you slip."

To help smokers get started on their pre-New Year's resolutions, NicoDerm CQ is offering a new bonus pack, which offers a free week of nicotine patches during a smoker's first step of therapy. For more information, smokers looking to quit can visit

Over-the-counter therapeutic nicotine products like the NicoDerm CQ patch, Nicorette gum and Commit lozenge are first-line treatments for smoking cessation and are thoroughly researched, well-understood and highly accessible stop smoking therapies.(4) GlaxoSmithKline Consumer Healthcare's therapeutic nicotine products are available without a doctor's prescription, in flexible dosing options at over 35,000 retail outlets across the country.(5) So a smoker who wants to quit doesn't have to wait to see a doctor to get help.

About NicoDerm CQ patch

NicoDerm CQ is the number one doctor-recommended patch to quit smoking. In fact, no treatment -- prescription or OTC -- is proven more effective than Nicoderm CQ in helping smokers quit long term.(5) NicoDerm CQ comes in three different strengths -- all specially formulated to control the release of nicotine for 24 hours. As cravings begin to diminish, this three-step process provides smokers with a lower dosage in each step, which allows a smoker to wean off nicotine gradually and safely. As with any treatment, failure to adhere to dosing instructions on the product label can limit effectiveness. When used as directed, NicoDerm CQ allows a smoker's body to gradually adjust to having less nicotine until eventually he doesn't need any at all. It also helps calm the cravings that make quitting smoking so hard by preventing cravings before they occur and providing more effective relief of cravings than willpower alone. Research has shown that using NicoDerm CQ to quit smoking significantly improves your chances of quitting successfully versus quitting cold turkey.(3)

About GlaxoSmithKline Consumer Healthcare

GlaxoSmithKline Consumer Healthcare is one of the world's largest over-the-counter consumer healthcare products companies. Its more than 30 well-known brands include the leading smoking cessation products, Nicorette(R) and NicoDerm(R)CQ(R), and Commit(R), as well as many medicine cabinet staples -- alli(R), Aquafresh(R), Sensodyne(R), and TUMS(R) -- which are trademarks owned by and/or licensed to GlaxoSmithKline Group of Companies.

About GlaxoSmithKline

GlaxoSmithKline -- one of the world's leading research-based pharmaceutical and healthcare companies -- is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For company information visit:

    (1) Survey of 808 adult smokers interested in quitting conducted by
        GlaxoSmithKline Consumer Healthcare in October 2006.
    (2) Shiffman S, Sweeney CT, Ferguson S, et al. Adherence with Nicotine
        Patch Dosing and Treatment Efficacy: Secondary Analysis of a 10-Week
        Randomized, Double-Blind, Placebo-Controlled Clinical Trial of
        Over-the-Counter Patch in Adult Smokers.
    (3) Stead LF, Perera R, Bullen C, Mant D, Lancaster T. Nicotine
        replacement therapy for smoking cessation. Cochrane Database of
        Systematic Reviews. 1996, Issue 3.
    (4) Fiore MC, Jaen CR, Baker TB, et al. Treating Tobacco Use and
        Dependence: 2008 Update. Clinical Practice Guideline. Rockville, MD:
        U.S. Department of Health and Human Services. Public Health Service.
        May 2008.
    (5) GSK Data on file.

     Contacts:          Mark Polisky, GolinHarris

                        Jennifer May, GlaxoSmithKline
                        Consumer Healthcare

SOURCE GlaxoSmithKline Consumer Healthcare
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Research on the effects of stem cell source and patient age on transplantation outcomes
2. Research highlights new approaches to prevent blood clots
3. 50 years of hairy-cell leukemia research to be observed
4. Event Honoring Bill Gates Raises Over $1.5 Million for Sustainable Agriculture Research at The Hebrew University of Jerusalem
5. New Research Reports on Interventions that May Alter the Course of Epilepsy Diagnosis and Management
6. Researchers & Department of Defense Question Multiple Vaccine Administration
7. Researchers gain new insight on wonder of cell division
8. HALT-C researchers: Interferon as long-term treatment for hepatitis C not effective
9. Jefferson researcher awarded NIH grant
10. Researcher develops screening tool to identify patients with prediabetes
11. Partnership for Peak Healthcare Performance Research Shows Consumers Lack Involvement in Managing Their Health
Post Your Comments:
(Date:11/30/2015)... ... 2015 , ... Trevor and Taylor Crabb have unveiled an exciting new ... represent the United States. This hybrid crowdfunding campaign is designed to provide ... in addition to offering corporate sponsors with some great marketing deliverables with the brothers ...
(Date:11/30/2015)... ... November 30, 2015 , ... 1Heart ... Convention of the Federation of Philippine American Chambers of Commerce held from November ... , 1Heart Caregiver Services, as an active delegate from the Philippine American ...
(Date:11/30/2015)... ... November 30, 2015 , ... Stress, anxiety, illness, infection ... parent worry about possible tumors? , Heather Spader, MD, a new pediatric neurosurgeon at ... common, some signs might point to tumors. , “Bad headaches that don’t ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... driverless vehicle experience this summer, ushering in a new era of publicly accessible ... and electric shuttle, will continue to offer guests an up-close look at the ...
(Date:11/30/2015)... ... 30, 2015 , ... The presidential race normally deals with political issues of ... a national news story when Donald Trump makes disparaging remarks about Hillary Clinton’s hairstyle? ... than anyone wants to admit when it comes to how people are viewed by ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... , Nov. 30, 2015   Royal Philips ... ScanWise Implant, the industry,s first MRI guided user interface ... scanning of patients with MR Conditional implants, such as ... the 2015 Radiological Society of North America Annual ... exams and supports diagnostic confidence of this growing patient ...
(Date:11/30/2015)... Nov. 30, 2015 Baxalta Incorporated ... leader dedicated to delivering transformative therapies to ... conditions, today announced the launch and first ... an extended circulating half-life recombinant factor VIII ... full-length ADVATE [Antihemophilic Factor (Recombinant)]. The treatment ...
(Date:11/30/2015)... PUNE, India , November 30, 2015 ... new market research report "Dental Lasers Market by Product (Soft ... Treatment, Periodontitis), End User (Hospitals, Clinics), and Geography - Global ... USD 224.7 Million by 2020, at a CAGR of 5.2% ... , Browse 140 market data Tables and 62 Figures spread ...
Breaking Medicine Technology: